Home > Articles > PARP enzymes and NAD+ consumption: how DNA repair uses cellular NAD+
PARP enzymes and NAD+ consumption: how DNA repair uses cellular NAD+
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
NAD+ has two jobs in the cell. It carries electrons in energy metabolism, where it is recycled rather than used up. It is also a raw material that some enzymes break apart. Among the enzymes that break it apart, the poly(ADP-ribose) polymerases, or PARPs, are some of the most studied. PARP1 in particular is described in the research literature as a major consumer of NAD+ in the nucleus, especially when DNA is damaged [1]. This explainer covers the chemistry, the idea that PARPs and sirtuins compete for the same NAD+ pool, and what cell and animal studies measure. For the wider picture of NAD+ biochemistry, see our NAD+ guide.
What a PARP enzyme does with NAD+
PARPs are a family of enzymes that transfer ADP-ribose units from NAD+ onto proteins. Each transfer splits one NAD+ molecule into two parts:
ADP-ribose, which is attached to a target protein
Nicotinamide, which is released as a by-product
Some family members add a single ADP-ribose unit (mono-ADP-ribosylation). PARP1 and PARP2 can build long, branched chains of ADP-ribose, called poly(ADP-ribose) or PAR. The process is called PARylation. Because every unit in a chain costs one NAD+, a long branched chain represents a substantial NAD+ expense [1].
The family is broader than DNA repair. A 2021 study in cancer cell lines reported that PARP16 adds ADP-ribose to ribosomal proteins, which reduced protein translation and was linked to how those cells handled protein load [2]. That finding is a reminder that "PARP activity" is not one thing, even if PARP1 dominates the DNA-damage story.
How DNA breaks switch PARP1 on
PARP1 sits on chromatin at relatively low activity. When it binds a single-strand or double-strand DNA break, its catalytic activity rises sharply. It then builds PAR chains on itself (automodification) and on nearby proteins such as histones [1]. Reviews describe several consequences of this burst:
Signalling. The negatively charged PAR chains act as a scaffold that recruits DNA repair proteins to the break.
Chromatin loosening. PARylated histones are thought to relax packed chromatin around the break.
Release. Heavily PARylated PARP1 loses its grip on DNA and dissociates, letting repair proceed.
PAR chains are short-lived. Degrading enzymes trim them back to free ADP-ribose, and the released nicotinamide can be fed back into NAD+ synthesis through the NAD+ salvage pathway. So under normal conditions, PARP activity is one loop in a cycle of NAD+ use and recycling [1].
When consumption outpaces supply
The picture changes when DNA damage is extensive. Reviews of pyridine nucleotide biology describe how strong, sustained PARP1 activation can drain cellular NAD+ faster than salvage can replace it. Because cells spend energy to rebuild NAD+, this has been proposed to deplete ATP as well, and in cell and animal models severe depletion has been linked to cell death [3].
This is why PARP1 appears in research on rare inherited disorders of DNA repair. A 2016 summary of work on accelerated-aging conditions with DNA repair defects described models in which persistent PARP1 activation was associated with lower NAD+ and changes in mitochondrial function [4]. A 2025 cell study of Werner syndrome-related WRN deficiency reported decreased mitochondrial NAD+ in WRN-deficient cells, which the authors linked to impaired proliferation [5]. Both are model-system findings, not measurements of everyday human ageing.
The PARP1 versus SIRT1 competition hypothesis
Sirtuins are another family of NAD+-consuming enzymes. SIRT1, which is largely nuclear, removes acetyl groups from proteins and splits NAD+ in the process. Because PARP1 and SIRT1 draw on the same nuclear NAD+ pool, researchers have proposed that they compete [6].
The argument has three parts, as laid out in a review of PARP-sirtuin crosstalk [6]:
Affinity. PARP1 is described as having a higher apparent affinity for NAD+ than SIRT1. When NAD+ drops, PARP1 should keep working while SIRT1 activity falls.
By-product. Both reactions release nicotinamide, which is itself an inhibitor of sirtuins. Heavy PARP activity could therefore suppress SIRT1 twice over.
Genetic tests. The review summarised mouse and cell experiments in which removing or inhibiting PARP1 was associated with higher NAD+ levels and markers of increased SIRT1 activity.
Newer animal work continues to probe this axis. A 2026 mouse study reported that loss of the protein GAL1 in liver cells led to PARP1 breakdown through the enzyme WWP2, accompanied by activation of a SIRT1-CPT1A pathway and less hepatic fat accumulation in that model [7].
Computational work has extended the idea to timekeeping. A 2015 modelling study predicted that NAD+ use by PARP1 during a DNA damage response could alter SIRT1 activity enough to shift circadian clock behaviour [8]. That is a model prediction, and it needs experimental confirmation.
The competition hypothesis is plausible and supported by genetic models, but it remains a hypothesis about relative fluxes. Compartments matter: nuclear, cytosolic and mitochondrial NAD+ pools are not perfectly mixed, and whole-cell NAD+ figures can hide large local differences.
What studies measure when DNA damage is high
When reading a paper on PARP and NAD+, it helps to know which readouts were used:
Readout | Typical method | What it tells researchers |
|---|---|---|
PAR levels | Antibody detection on blots or by microscopy | How much PARylation occurred |
Total NAD+ or NAD+/NADH | Enzymatic cycling assays or mass spectrometry | Size of the NAD+ pool in a sample |
ATP | Luminescence assays | Downstream energy status |
Sirtuin activity proxies | Acetylation of known SIRT1 targets | Indirect sign of sirtuin activity |
Genetic or chemical comparisons | PARP1 knockout cells or PARP inhibitors | Whether an effect depends on PARP1 |
PARP inhibitors deserve a note. They are widely used as laboratory tools to test whether an NAD+ change depends on PARP activity, and reviews have long discussed their wider research interest [9]. In this explainer they matter only as experimental controls.
Human tissue data are rarer. A 2012 study of human skin samples from donors of different ages reported higher PARP activity and lower NAD+ with age in some groups, alongside markers of oxidative stress [10]. It is one of the studies discussed in our page on whether NAD+ declines with age. Tissue assays like these are not comparable to consumer blood tests; our guide to reading an NAD+ test report explains why sample type changes the number.
Limits of the evidence
Most PARP-NAD+ data come from cultured cells and mice, often under deliberate DNA damage.
Whole-cell NAD+ measurements cannot resolve which compartment changed.
Competition between PARP1 and SIRT1 is inferred from genetic models; direct flux measurements in living human tissue are scarce.
None of this research establishes that any product changes PARP activity in people. For how NAD+-related products are classified, see our page on U.S. rules for NMN, NR and IV NAD+. Our sourcing approach is described on how this site works.
Further reading
Readers who want the enzymology in more depth usually do better with a solid textbook than with scattered reviews. When comparing molecular biology and metabolism books, useful criteria include: publication date (ADP-ribosylation research moved quickly after the early 2000s), whether DNA repair and redox metabolism get dedicated chapters, the quality of pathway figures, whether each chapter ends with primary references, the author's research background, and price across print, e-book and used editions. Our evidence-graded reading list applies similar criteria.
Frequently asked questions
Does PARP1 use up NAD+ permanently?
Each ADP-ribose unit added by PARP1 splits one NAD+ molecule. The nicotinamide released can be recycled back into NAD+ through the salvage pathway, so under normal conditions the loss is temporary. Extensive DNA damage can push consumption beyond what recycling replaces, according to cell and animal studies [3].
What is the difference between PARP1 and PARP2?
Both build poly(ADP-ribose) chains at DNA breaks. Reviews describe PARP1 as responsible for most damage-induced PARylation, with PARP2 contributing a smaller share [1].
Is the PARP-sirtuin competition proven in humans?
No. The idea rests mainly on enzyme properties and on mouse and cell experiments in which removing PARP1 raised NAD+ and sirtuin activity markers [6]. Direct human measurements of this competition are limited.
Why do PARP studies use inhibitors?
Inhibitors let researchers check whether a fall in NAD+ depends on PARP activity. If blocking PARP prevents the drop, the change is attributed to PARP consumption [9].
Related on this site
NAD+ explained: biochemistry, precursors, testing and human evidence
Reading an NAD+ test report: units, sample types and reference ranges
Last updated: 23 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.